stockrowMannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024.
- Revenue
- +24.0%
- EPS
- −333.3%
- Free cash flow
- −267.7%
- Total debt
- +201.8%
Quarter to September 2026, against a year earlier
Follow MNKD
Alert me
MannKind Corporation (MNKD) EV/Sales
As of 6 November 2026, MannKind Corporation (MNKD) trades at a EV/Sales of 3.8×. Over the past ten years it has ranged from 0.0× (September 2016) to 43.2× (October 2017); the current reading is higher than 28% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.8× | (3.21%) |
| FY2024 | 6.0× | 5.81% |
| FY2023 | 5.7× | (63.53%) |
| FY2022 | 15.5× | (4.79%) |
| FY2021 | 16.3× | 40.95% |
| FY2020 | 11.5× | 126.78% |
| FY2019 | 5.1× | (22.73%) |
| FY2018 | 6.6× | (79.94%) |
| FY2017 | 32.8× | 1,278.80% |
| FY2016 | 2.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.8× | (7.93%) |
| Jun 2026 | 4.1× | 43.03% |
| Mar 2026 | 2.9× | (50.03%) |
| Dec 2025 | 5.8× | 13.45% |
| 37 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| MNKD MannKind Corporation | 3.8× |
| URGN Urogen Pharma compare | 5.4× |
| OMER Omeros Corporation compare | 12.3× |
| NKTR Nektar Therapeutics compare | 19.2× |
| INBX Inhibrx Biosciences, Inc. compare | 439× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 1,025× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)